Boston Scientific Corporation $BSX Stock Holdings Increased by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale lifted its position in Boston Scientific Corporation (NYSE:BSX) by 8.7% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 1,844,793 shares of the medical equipment provider’s stock after buying an additional 147,932 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Boston Scientific were worth $195,338,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. HM Payson & Co. grew its stake in shares of Boston Scientific by 1.4% in the 1st quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider’s stock valued at $694,000 after buying an additional 98 shares in the last quarter. IVC Wealth Advisors LLC grew its stake in shares of Boston Scientific by 4.9% in the 2nd quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock valued at $236,000 after buying an additional 102 shares in the last quarter. Park Square Financial Group LLC grew its stake in shares of Boston Scientific by 5.2% in the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider’s stock valued at $208,000 after buying an additional 103 shares in the last quarter. HHM Wealth Advisors LLC grew its stake in shares of Boston Scientific by 13.2% in the 1st quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider’s stock valued at $89,000 after buying an additional 103 shares in the last quarter. Finally, Rise Advisors LLC grew its stake in shares of Boston Scientific by 13.9% in the 1st quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider’s stock valued at $85,000 after buying an additional 103 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the company’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director owned 18,479 shares in the company, valued at $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 174,214 shares of company stock valued at $17,972,457. Company insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on BSX shares. Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 11th. Truist Financial boosted their target price on Boston Scientific from $125.00 to $129.00 and gave the stock a “buy” rating in a report on Wednesday, October 1st. BTIG Research boosted their target price on Boston Scientific from $127.00 to $132.00 and gave the stock a “buy” rating in a report on Wednesday, October 1st. Finally, Barclays boosted their target price on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a report on Thursday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Buy” and an average price target of $120.71.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $100.56 on Tuesday. The business has a fifty day simple moving average of $101.25 and a 200 day simple moving average of $101.85. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $149.01 billion, a price-to-earnings ratio of 59.86, a PEG ratio of 2.39 and a beta of 0.61. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific’s revenue was up 22.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.